Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bard’s LifeStent Gets Legs: PMA Approved For Femoral, Popliteal Arteries

This article was originally published in The Gray Sheet

Executive Summary

C.R. Bard is now able to market its LifeStent for treating occluded leg arteries with a PMA approval announced Feb. 17

You may also be interested in...



Abbott Makes Good On IDev Buy With Supera Peripheral Stent Approval

Abbott announced PMA-approval of the Supera stent, which it gained in a $310 million acquisition of IDev Technologies last year. The approval gives Abbott a device specific for the superficial femoral artery, which the company says is one of the largest and fastest growing segments of the peripheral stent market.

Stents Vs. Balloons Question For Peripheral Artery Disease Gets Attention At Veith

The presence of the first drug-eluting stent on the U.S. market to treat peripheral artery disease is certainly not the end of the discussion for how peripheral artery patients will be treated, clinicians made clear at the influential Veith Symposium this month.

TCT Conference In Brief

Clinical data news from the Transcatheter Cardiovascular Therapeutics conference held last week in Miami.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT027123

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel